---
title: "Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284050212.md"
description: "Altimmune has raised approximately $211 million through an underwriting agreement to sell 64.25 million shares of common stock and up to 10.75 million pre-funded warrants, priced at $3.00 and $2.999 respectively. The offering, led by Leerink Partners and Barclays Capital, closed on April 24, 2026. The funds will support Phase 3 development of pemvidutide, pre-commercial activities, and general corporate purposes."
datetime: "2026-04-24T20:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284050212.md)
  - [en](https://longbridge.com/en/news/284050212.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284050212.md)
---

# Altimmune Raises ~$211 Million in Stock-and-Warrant Offering Led by Leerink and Barclays

Altimmune entered into an underwriting agreement to sell 64.25 million shares of common stock with accompanying warrants and up to 10.75 million pre-funded warrants, at public offering prices of $3.00 per share and $2.999 per pre-funded warrant. The offering closed on Apr 24, 2026 and is expected to yield approximately $211.2 million in net proceeds. The company plans to fund Phase 3 development of pemvidutide in MASH, initiate pre-commercial activities, and for general corporate purposes.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for public offering of common stock and warrants
-   **Counterparty**: Leerink Partners and Barclays Capital, as representatives of the underwriters
-   **Signed / Effective**: Apr 22 2026 / same
-   **Reason**: Fund Phase 3 pemvidutide, pre-commercial work, and corporate purposes

Original SEC Filing: Altimmune, Inc. \[ ALT \] - 8-K - Apr. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)